Skip to main content
The Journal of Physiology logoLink to The Journal of Physiology
. 2007 Aug 9;584(Pt 2):381–387. doi: 10.1113/jphysiol.2007.138875

Compartmentalized NMDA receptor signalling to survival and death

Francesc X Soriano 1, Giles E Hardingham 1
PMCID: PMC2277150  PMID: 17690142

Abstract

The ability of Ca2+ influx through the N-methyl d-aspartate subclass of glutamate receptor (NMDA receptor) to both kill neurons and to promote survival under different circumstances is well established. Here we discuss the signal pathways that mediate this dichotomous signalling, and the factors that influence whether an NMDA receptor-dependent Ca2+ signal results in a net pro-survival or pro-death effect. The magnitude of NMDA receptor activation, be it intensity or duration, is of course very important in determining the nature of the response to an episode of NMDA receptor activity, with excitotoxic death pathways requiring higher levels than survival pathways. However, the NMDA receptor is not merely a conduit for Ca2+ influx: the consequences of NMDA receptor activity can be influenced by signalling molecules that physically associate with the NMDA receptor or indeed the location (synaptic versus extrasynaptic) of the receptor. Furthermore, we discuss the possibility that the Ca2+ effectors of survival and death are in different subcellular locations, and thus depend on the spatial characteristics of the Ca2+ transient. A greater understanding of these issues may point to ways of selectively blocking pro-death signalling in neurological disorders such as stroke, where global NMDA receptor antagonists have proved ineffective.


It is long-established that high levels of glutamate kill neurons (Lucas & Newhouse, 1957; Olney, 1969). During an ischaemic episode, extracellular glutamate builds up due to synaptic release and impaired/reversed uptake mechanisms (Rossi et al. 2000; Camacho & Massieu, 2006). This glutamate induces excessive activation of the N-methyl d-aspartate subclass of glutamate receptor (NMDAR) which results in Ca2+-dependent cell death (Arundine & Tymianski, 2004). Zn2+ influx and release from internal sites also contribute to ischaemic injury (Sensi & Jeng, 2004). However, while influx has been reported to take place through NMDARs, elevation of Zn2+ levels takes place mainly via other routes (Sensi & Jeng, 2004); NMDAR signalling to cell death is predominantly Ca2+ dependent. Excessive NMDAR activity can lead to cell death in other acute events such as mechanical trauma and seizure, and may contribute to chronic neurodegeneration in Alzheimer's disease (Lipton & Rosenberg, 1994; Chohan & Iqbal, 2006). The destructive effects of excessive NMDAR activity are in no doubt, nor the protective effects of NMDAR antagonists in blocking several animal models of neuronal injury. Nevertheless, a number of recent studies have shown that in some circumstances, survival of several neuronal types is dependent on physiological synaptic NMDAR activity (Ikonomidou & Turski, 2002; Hardingham & Bading, 2003). While elimination of NMDA receptor activity in vivo has long been established as protective in many excitotoxic scenarios, it causes widespread apoptosis and enhances trauma-induced injury in developing neurons (Gould et al. 1994; Ikonomidou et al. 1999; Pohl et al. 1999; Adams et al. 2004). In the adult CNS, NMDAR blockade exacerbates neuronal loss when applied after traumatic brain injury and during ongoing neurodegeneration (Ikonomidou et al. 2000), and prevents the survival of newborn neurons in the adult dentate gyrus (Tashiro et al. 2006). In most of these in vivo studies, the pro-survival role of NMDAR activity is exposed by the harmful effects of pharmacological blockade of normal physiological NMDAR activity. It is unclear whether elevating activity above this level would have a greater protective effect, or begin to have an excitotoxic effect. Responses of neurons to glutamate or NMDA follow a bell-shaped curve: both too much and too little NMDAR activity can be potentially harmful (Lipton & Nakanishi, 1999). This dose–response is consistent with the observation that too much and too little intracellular Ca2+ is harmful to neurons (Lipton & Kater, 1989). However, the NMDAR is not merely a conduit for Ca2+ influx, the consequences of NMDAR activity can be influenced by signalling molecules that physically associate with the NMDAR, the location (synaptic versus extrasynaptic) of the receptor, or the nature of the stimulation (chronic/low level versus transient/saturating).

Clinical trials for stroke with NMDA receptor antagonists have been unsuccessful

Despite an overwhelming body of evidence from animal studies implicating NMDAR activity in neuronal loss following ischaemia, the many clinical trials of different NMDAR antagonists for stroke have failed due to poor tolerance and efficacy (Ikonomidou & Turski, 2002; Muir, 2006). The fact that the NMDAR plays a central role in synaptic plasticity and transmission, and learning and cognition accounts for the undesired psychomimetic and CNS-adverse effects of antagonists (Muir, 2006). However, trial design may have been erring too far on the side of caution in seeking to avoid psychosis and other CNS-adverse effects, when these side-effects are on-target and not off-target effects. Other issues cloud a clear assessment of NMDAR antagonists, such as numbers of patients within the trials and time taken to administrate the drug. With many large pharmaceutical companies shying away from NMDAR antagonists, these issues may not be resolved any time soon.

Nevertheless, the growing body of evidence that physiological synaptic NMDAR activity exerts a neuroprotective effect has led to suggestions that it may play a role in promoting recovery and preventing delayed neuronal loss in the penumbra (Albers et al. 2001; Ikonomidou & Turski, 2002). Thus, global NMDAR antagonists may block NMDAR-activated pro-survival signals triggered in response to an ischaemic challenge, but interfere with some recovery or preconditioning processes in the penumbra. The anti-excitotoxic effects of NMDAR antagonists have never been in question, but until relatively recently the pro-survival role of the NMDAR was not known and so antagonists were not tested in contexts that would expose their harmful effects. In treating disorders associated with pro-death NMDAR signalling, it may be desirable to block pro-death signalling, without affecting pro-survival signalling or synaptic plasticity. This will require a thorough understanding of the nature of both survival and death pathways triggered by the NMDAR, and the factors that make an episode of NMDAR activity promote survival or death. Although the signals that mediate NMDAR signalling to death and survival are discussed in more detail elsewhere (Hardingham & Bading, 2003; Arundine & Tymianski, 2004; Hardingham, 2006; Hetman & Kharebava, 2006), there follows a very brief overview.

Death and survival signalling from the NMDAR

There are several fundamental mechanisms implicated in NMDAR-dependent cell death. In instances of extremely high NMDAR activity, simple Ca2+ overload may mediate fast necrotic cell death. However, in many cases, active mechanisms are implicated, even in what would be classically described as necrotic cell death. Mitochondrial dysfunction caused by excessive Ca2+ uptake by the mitochondria through the potential-driven uniporter (Stout et al. 1998) is one mechanism. The mitochondrial membrane becomes depolarized due to this uptake, which inhibits ATP production, and can cause depletion of cytosolic ATP due to reversal of the mitochondrial ATPase, resulting in loss of ion homeostasis and rapid cell death. In cases where mitochondrial depolarization and dysfunction are only partial, neuronal apoptosis may be triggered (Ankarcrona et al. 1995), for example due to cytochrome c release. In addition to causing mitochondrial dysfunction, toxic levels of NMDAR activation cause Ca2+ efflux to be impaired (Bano et al. 2005; Pottorf et al. 2006). Calpains, Ca2+-dependent proteases, are activated by the excessive NMDAR-mediated Ca2+ influx and cleave a major isoform of the plasma membrane Na+–Ca2+ exchanger (NCX3) impairing its function (Bano et al. 2005). The plasma membrane Ca2+-ATPase pump (PMCA), which would utilize the energy from ATP hydrolysis to transport Ca2+ across the plasma membrane, is inactivated by excitotoxic insults via mechanisms attributed to both caspases (Schwab et al. 2002) and calpains (Pottorf et al. 2006). NMDAR activity-regulated overactivation of the Ca2+-dependent nNOS (neuronal nitric oxide synthase) also has toxic downstream responses, including mitochondrial dysfunction, p38 mitogen-activated protein kinase signalling and TRPM (transient receptor potential melastatin) channel activation (Aarts et al. 2003; Arundine & Tymianski, 2004).

The PI3K (phosphoinositide-3-kinase)–Akt kinase cascade is a key signalling pathway responsible for the pro-survival effects of NMDAR activity (Lafon-Cazal et al. 2002; Papadia et al. 2005; Soriano et al. 2006). Akt phosphorylates and inactivates GSK3 (glycogen synthase kinase-3β; Cross et al. 1995), and also triggers phosphorylation and nuclear export of the FOXO (forkhead box O) subfamily of forkhead transcription factors, promoting down-regulation of pro-death genes such as Fas ligand (Brunet et al. 1999). NMDAR signalling to Akt-dependent FOXO export has also been observed in the context of NMDAR signalling (Soriano et al. 2006). Akt also inactivates the pro-apoptotic Bcl-2 family member BAD (Bcl-2/Bcl-XL-antagonist causing cell death), the JNK/p38 activator ASK1 (Kim et al. 2001), and also the pro-death transcription factor p53 (Yamaguchi et al. 2001).

Another key mediator of activity-dependent gene expression is the transcription factor CREB, which binds to the cAMP response element (CRE) and promotes expression of a number of pro-survival genes. CREBdependent gene expression is causally linked to the long-lasting phase of synaptic NMDAR-dependent neuroprotection against apoptotic insults (Papadia et al. 2005). A recent study identified two genes that contribute to synaptic NMDAR-dependent neuroprotection (Zhang et al. 2007): Btg2, a potentially anti-apoptotic CREB target gene, and Bcl6, a transcriptional repressor implicated in suppression of p53, also potentially a CREB target. Another CRE-regulated candidate is the pro-survival neurotrophin BDNF (brain-derived neurotrophic factor), which is up-regulated by NDMAR activity (Hardingham et al. 2002) and is known to promote neuronal survival (Shieh et al. 1998; Hetman & Kharebava, 2006). NMDAR blockade in vivo reduces BDNF mRNA expression and in vitro supplementation of neurons with BDNF can rescue them from NMDAR antagonist-caused neuronal death (Hansen et al. 2004).

Stimulus intensity is important in determining the outcome of an episode of NMDAR activity

The magnitude of activation, be it intensity or duration, is very important in determining the nature of the response to an episode of NMDAR activity. The classical bell-shaped curve model of the neuronal response to NMDA or glutamate implies that the Ca2+ effectors of pro-survival signalling have a higher affinity (i.e. considerably lower requirements for Ca2+) than the Ca2+ effectors of death. Therefore the Ca2+ concentration threshold for activating key pro-survival signalling cascades such as PI3K, ERK1/2 (extracellular signal-regulated kinase 1/2) and CREB's activator CaMKIV (Ca2+–calmodulin-dependent protein kinase IV) must be lower than that necessary to trigger toxic levels of calpain activation, mitochondrial Ca2+ uptake or NO production. The key Ca2+-dependent components of the survival pathways are in the main activated not by Ca2+ directly, but by Ca2+–calmodulin. Calmodulin is a ubiquitous Ca2+-binding protein which changes conformation when it binds to Ca2+. Ca2+–calmodulin then activates a number of downstream signals, including CaMKIV, PI3K and upstream activators of ERK1/2. As a physiological sensor of elevated Ca2+ levels, calmodulin is designed to be significantly activated by relatively modest increases in Ca2+ (around 1 μm), particularly in vivo, or in the presence of its downstream effectors (Bayley et al. 1996; Torok et al. 1998).

In contrast, central mediators of NMDAR-dependent cell death, calpains, are not Ca2+–calmodulin dependent but are activated by Ca2+ directly, and require higher levels to be fully induced: half-maximal activity is around 4 μm for μ-calpain, and far higher for m-calpain, even in the presence of μ-calpain (Baki et al. 1996; Tompa et al. 1996). The same can be said of the mitochondrial uniporter, which senses Ca2+ directly and is only weakly active at < 2–3 μm Ca2+ (Nicholls, 2004). Furthermore, it is likely that toxic levels of matrix Ca2+ are only achieved when cytoplasmic levels are far higher than this. Another Ca2+-dependent promoter of neuronal death, nNOS, is Ca2+–calmodulin dependent and indeed plays important roles in non-pathological signalling processes such as synaptic plasticity. However, nNOS is also regulated by phosphorylation, and a recent study showed that, in contrast to non-toxic stimuli, high levels of glutamate fail to trigger an inhibitory phosphorylation event that ensures that nNOS activation is transient (Rameau et al. 2007). Thus, nNOS becomes excessively active and contributes to excitotoxic cell death (Rameau et al. 2007).

Where in the neuron are the Ca2+ effectors of survival and death?

As stated earlier, in treating disorders associated with pro-death NMDAR signalling, it would be desirable to be able to interfere with pro-death signalling from the NMDAR, while sparing pro-survival signals. While death and survival signalling pathways are both activated by Ca2+ influx, a greater knowledge as to the spatial Ca2+ requirements to activate these pathways may aid in their selective inhibition, and enhance our understanding of the dichotomous nature of NMDAR signalling. Recent studies suggest that the Ca2+ effectors of survival and death exist in different parts of the cell, potentially requiring different protein–protein interactions thus pointing to more specific ways of targeting of pro-death events.

NMDAR signalling to neuronal death may involve mitochondrial, and membrane proximal events

Neurons do not respond in a stereotypical way to Ca2+ influx: the channel through which Ca2+ enters can affect the response (Bading et al. 1993; Hardingham et al. 1999; Dolmetsch et al. 2001). In the case of excitotoxicity, Ca2+ influx specifically through NMDARs promotes cell death more efficiently than through voltage-gated Ca2+ channels (Tymianski et al. 1993; Arundine & Tymianski, 2004). An explanation for this, the ‘source-specificity hypothesis’, proposes that neuron-specific enzymes or substrates responsible for Ca2+-dependent excitotoxicity are co-localized with NMDARs. The cytoplasmic tail of NMDAR subunits are linked to a network of neuronal proteins, the so-called NMDAR signalling complex. A role for this complex in mediating NMDAR-dependent death was shown in the case of nNOS, which is linked to NR2 subunits via PSD-95. When the interaction of NR2B and PSD-95 was disrupted, the NMDAR was uncoupled from NO production, reducing excitotoxic signalling (Aarts et al. 2002). An important target of NMDAR signalling to NO production in excitotoxicity is the cation channel TRPM7 (Aarts et al. 2003). NMDAR-dependent Ca2+ influx triggers both NO production via nNOS activation and superoxide production via mitochondrial Ca2+ uptake, which combine to form ONOO, an activator of TRPM7. Since TRPM7 itself passes Ca2+, this results in a positive feedback loop.

Other membrane-proximal events that contribute to excitotoxicity involve impairment of Ca2+ efflux (Schwab et al. 2002; Bano et al. 2005; Pottorf et al. 2006). As stated earlier, both NCX and PMCA are targeted for cleavage and inactivation by calpains and caspases. While by definition these events take place at the plasma membrane, the locus at which Ca2+ acts to initiate these events is unclear, although caspase activation may require mitochondrial depolarization to initiate cytochrome c release. Indeed, as discussed earlier, mitochondrial dysfunction caused by excessive Ca2+ uptake by the mitochondria through the potential-driven uniporter is a key mechanism by which NMDAR activity promotes cell death (Stout et al. 1998).

NMDAR-activated survival pathways involve nuclear Ca2+ signalling

Activation of CREB-dependent gene expression is strongly induced by synaptic NMDAR activity (Hardingham et al. 2002). Ca2+ influx through the synaptic NMDAR activates the Ras/ERK pathway in the cytoplasm and the nuclear Ca2+–calmodulin-dependent protein kinases, principally CaMKIV. CaMKIV mediates fast CREB phosphorylation at Ser-133, whereas the ERK1/2 pathway promotes CREB phosphorylation in a slower, more long-lasting manner (Hardingham et al. 2001a; Wu et al. 2001). Ser-133 phosphorylation of CREB is necessary to recruit CBP (CREB-binding protein), a transcriptional cofactor, to CREB. The transactivation potential of CBP is itself positively regulated by NMDAR activity (Hardingham et al. 1999) by a mechanism involving its phosphorylation on Ser-301 by CaMKIV (Impey et al. 2002). Gene expression mediated by CREB can also be mediated by another family of CREB coactivators, the TORCs (transducers of regulated CREB activity; Screaton et al. 2004).

Elevation of Ca2+ within the nucleus is important for full activation of CREB-dependent gene expression (Hardingham et al. 1997, 2001b; Papadia et al. 2005), probably due to the nuclear localization of CREB and CBP's activator CaMKIV. CREB-dependent gene expression is causally linked to the long-lasting phase of synaptic NMDAR-dependent neuroprotection against apoptotic insults (Papadia et al. 2005). This long-lasting phase is also dependent on nuclear Ca2+–calmodulin signalling (Papadia et al. 2005), consistent with the requirement for nuclear Ca2+ in CREB activation. Furthermore, activity-dependent induction of prosurvival genes Bcl6 and Btg2 also rely on nuclear Ca2+ signalling. Interestingly, nuclear Ca2+ is also implicated in regulating memory consolidation (Limback-Stokin et al. 2004), though whether this is via CREB activation is not known. Thus the nucleus is a major site for physiological effects of NMDAR signalling. However, it appears not to play a role in excitotoxic cell death since inhibition of Ca2+–calmodulin signalling does not interfere with NMDAR-dependent excitotoxic cell death (G. E. Hardingham, unpublished observations).

The other key pro-survival signalling cassette induced by synaptic NMDAR activity is the PI3K–Akt pathway (Hetman & Kharebava, 2006). This pathway exerts multiple effects in the cytoplasm (see above) and is thought to be activated by cytoplasmic Ca2+ elevation, probably due to the Ca2+–calmodulin dependence of PI3K (Joyal et al. 1997). While synaptic activity is ongoing, the PI3K–Akt pathway is sufficient to mediate NMDAR-dependent neuroprotection (i.e. CREB activation is not required; Papadia et al. 2005). Activation of the PI3K–Akt pathway does not rely on nuclear Ca2+ signalling (G. E. Hardingham, unpublished observations) and consistent with this, the PI3K-dependent, CREB-independent phase of neuroprotection also does not require nuclear Ca2+ signalling (Papadia et al. 2005). Furthermore, PI3K activation requires elevation of bulk cytoplasmic Ca2+ and is not activated by submembranous Ca2+ (G. E. Hardingham, unpublished observations). Thus, it appears that in cortical neurons, the NMDAR-activated mediators of survival and death have different spatial requirements for Ca2+.

Influence of the location of the receptor on the nature of NMDAR signalling

Aside from stimulus intensity, the location of the NMDAR may also profoundly affect the signals that emanate from the NMDAR. Developing neurons have sizeable pools of NMDARs at extrasynaptic, as well as synaptic locations, which signal very differently. Ca2+ influx dependent on intense synaptic NMDAR activation is well tolerated by cells whereas activation of extrasynaptic NMDARs, either on their own or in the presence of synaptic NMDAR activation, causes a loss of mitochondrial membrane potential and cell death (Hardingham et al. 2002).

Differential synaptic versus extrasynaptic NMDAR effects also extend to other signal pathways. While synaptic NMDAR activity strongly induces CREB-dependent gene expression, extrasynaptic NMDARs are coupled to a CREB shut-off pathway (Hardingham et al. 2002) in a developmentally regulated manner (Hardingham & Bading, 2002). It has also been shown that there is opposing regulation of the ERK1/2 pathway by synaptic and extrasynaptic NMDARs in hippocampal neurons: synaptic NMDARs activate the ERK pathway whereas extrasynaptic NMDARs evoke ERK inactivation (Ivanov et al. 2006). A recent study involving genome-wide expression analysis has extended our understanding of synaptic versus extrasynaptic signalling (Zhang et al. 2007). While synaptic NMDARs activated a number of pro-survival genes (including the aforementioned Btg2 and Bcl6), extrasynaptic NMDARs failed to do this, and in fact activated expression of a gene, Clca1, which kills neurons. It will be of interest to know whether Clca1 is activated in vivo during excitotoxic trauma, and whether it represents a potential therapeutic target.

The molecular basis for the apparent differences in synaptic/extrasynaptic NMDAR signalling could be due to differences in the way these two populations of receptors become stimulated, since the former are stimulated transsynaptically with transiently saturating levels of glutamate, while the latter can only be activated chronically by extracellular glutamate. Thus, generating similar Ca2+ loads via these different stimulation protocols could conceivably activate different signalling cascades. Also, the composition of the synaptic versus extrasynaptic NMDAR signalling complexes as opposed to the location of the receptors per se may be critical, though these potential differences await study. Tied in with this is the possibility that differences in receptor subunit composition, rather than location, are important, although there is little evidence that differences in subunit composition are dramatic enough to explain the effects observed (Thomas et al. 2006). However, a recent study has contended that NR2B-containing NMDARs tend to promote neuronal death, irrespective of location (synaptic or extrasynaptic) while NR2A-containing NMDARs promote survival (Liu et al. 2007). The investigation of subunit-specific differences in NMDAR signalling is hampered by the lack of a NR2A-specific antagonist that is sufficiently selective to discriminate in the physiological scenario of trans-synaptic stimulation (Frizelle et al. 2006; Neyton & Paoletti, 2006).

Conclusions

We have an increasing understanding as to the molecular mechanisms of NMDAR signalling to survival and death. This has led to an appreciation of how different signal cascades require different levels of Ca2+, and indeed how the spatial properties of the Ca2+ signal may also be important. Recent studies suggest a central role of nuclear Ca2+ signalling in regulating pro-survival gene expression. In contrast, mitochondria, and certain membrane-proximal interactions appear to be important for pro-death signalling. A knowledge of where in the neuron Ca2+ is acting to exert pro-death or pro-survival effects may aid in selectively uncoupling the NMDAR from harmful consequences.

Acknowledgments

The authors' work is supported by the Royal Society, the European Commission, the Wellcome Trust, the BBSRC and Medical Research Scotland.

References

  1. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. Cell. 2003;115:863–877. doi: 10.1016/s0092-8674(03)01017-1. [DOI] [PubMed] [Google Scholar]
  2. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor–PSD-95 protein interactions. Science. 2002;298:846–850. doi: 10.1126/science.1072873. [DOI] [PubMed] [Google Scholar]
  3. Adams SM, de Rivero Vaccari JC, Corriveau RA. Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J Neurosci. 2004;24:9441–9450. doi: 10.1523/JNEUROSCI.3290-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Albers GW, Goldstein LB, Hall D, Lesko LM. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA. 2001;286:2673–2682. doi: 10.1001/jama.286.21.2673. [DOI] [PubMed] [Google Scholar]
  5. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P. Glutamateinduced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995;15:961–973. doi: 10.1016/0896-6273(95)90186-8. [DOI] [PubMed] [Google Scholar]
  6. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci. 2004;61:657–668. doi: 10.1007/s00018-003-3319-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science. 1993;260:181–186. doi: 10.1126/science.8097060. [DOI] [PubMed] [Google Scholar]
  8. Baki A, Tompa P, Alexa A, Molnar O, Friedrich P. Autolysis parallels activation of μ-calpain. Biochem J. 1996;318:897–901. doi: 10.1042/bj3180897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, Nicotera P. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005;120:275–285. doi: 10.1016/j.cell.2004.11.049. [DOI] [PubMed] [Google Scholar]
  10. Bayley PM, Findlay WA, Martin SR. Target recognition by calmodulin: dissecting the kinetics and affinity of interaction using short peptide sequences. Protein Sci. 1996;5:1215–1228. doi: 10.1002/pro.5560050701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–868. doi: 10.1016/s0092-8674(00)80595-4. [DOI] [PubMed] [Google Scholar]
  12. Camacho A, Massieu L. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Arch Med Res. 2006;37:11–18. doi: 10.1016/j.arcmed.2005.05.014. [DOI] [PubMed] [Google Scholar]
  13. Chohan MO, Iqbal K. From tau to toxicity: Emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis. 2006;10:81–87. doi: 10.3233/jad-2006-10112. [DOI] [PubMed] [Google Scholar]
  14. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789. doi: 10.1038/378785a0. [DOI] [PubMed] [Google Scholar]
  15. Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME. Signaling to the nucleus by an L-type calcium channel–calmodulin complex through the MAP kinase pathway. Science. 2001;294:333–339. doi: 10.1126/science.1063395. [DOI] [PubMed] [Google Scholar]
  16. Frizelle PA, Chen PE, Wyllie DJA. Equilibrium constants for NVP-AAM077 acting at recombinant NR1/NR2A and NR1/NR2B NMDA receptors: implications for studies of synaptic transmission. Mol Pharmacol. 2006;70:1022–1032. doi: 10.1124/mol.106.024042. [DOI] [PubMed] [Google Scholar]
  17. Gould E, Cameron HA, McEwen BS. Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J Comp Neurol. 1994;340:551–565. doi: 10.1002/cne.903400408. [DOI] [PubMed] [Google Scholar]
  18. Hansen HH, Briem T, Dzietko M, Sifringer M, Voss A, Rzeski W, Zdzisinska B, Thor F, Heumann R, Stepulak A, Bittigau P, Ikonomidou C. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis. 2004;16:440–453. doi: 10.1016/j.nbd.2004.03.013. [DOI] [PubMed] [Google Scholar]
  19. Hardingham GE. Pro-survival signalling from the NMDA receptor. Biochem Soc Trans. 2006;34:936–938. doi: 10.1042/BST0340936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hardingham GE, Arnold FJ, Bading H. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci. 2001a;4:565–566. doi: 10.1038/88380. [DOI] [PubMed] [Google Scholar]
  21. Hardingham GE, Arnold FJ, Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat Neurosci. 2001b;4:261–267. doi: 10.1038/85109. [DOI] [PubMed] [Google Scholar]
  22. Hardingham GE, Bading H. Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim Biophys Acta. 2002;1600:148–153. doi: 10.1016/s1570-9639(02)00455-7. [DOI] [PubMed] [Google Scholar]
  23. Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003;26:81–89. doi: 10.1016/S0166-2236(02)00040-1. [DOI] [PubMed] [Google Scholar]
  24. Hardingham GE, Chawla S, Cruzalegui FH, Bading H. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron. 1999;22:789–798. doi: 10.1016/s0896-6273(00)80737-0. [DOI] [PubMed] [Google Scholar]
  25. Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature. 1997;385:260–265. doi: 10.1038/385260a0. [DOI] [PubMed] [Google Scholar]
  26. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405–414. doi: 10.1038/nn835. [DOI] [PubMed] [Google Scholar]
  27. Hetman M, Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem. 2006;6:787–799. doi: 10.2174/156802606777057553. [DOI] [PubMed] [Google Scholar]
  28. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283:70–74. doi: 10.1126/science.283.5398.70. [DOI] [PubMed] [Google Scholar]
  29. Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci U S A. 2000;97:12885–12890. doi: 10.1073/pnas.220412197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1:383–386. doi: 10.1016/s1474-4422(02)00164-3. [DOI] [PubMed] [Google Scholar]
  31. Impey S, Fong AL, Wang Y, Cardinaux JR, Fass DM, Obrietan K, Wayman GA, Storm DR, Soderling TR, Goodman RH. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron. 2002;34:235–244. doi: 10.1016/s0896-6273(02)00654-2. [DOI] [PubMed] [Google Scholar]
  32. Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006;572:789–798. doi: 10.1113/jphysiol.2006.105510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB. Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem. 1997;272:28183–28186. doi: 10.1074/jbc.272.45.28183. [DOI] [PubMed] [Google Scholar]
  34. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21:893–901. doi: 10.1128/MCB.21.3.893-901.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lafon-Cazal M, Perez V, Bockaert J, Marin P. Akt mediates the anti-apoptotic effect of NMDA but not that induced by potassium depolarization in cultured cerebellar granule cells. Eur J Neurosci. 2002;16:575–583. doi: 10.1046/j.1460-9568.2002.02124.x. [DOI] [PubMed] [Google Scholar]
  36. Limback-Stokin K, Korzus E, Nagaoka-Yasuda R, Mayford M. Nuclear calcium/calmodulin regulates memory consolidation. J Neurosci. 2004;24:10858–10867. doi: 10.1523/JNEUROSCI.1022-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lipton SA, Kater SB. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci. 1989;12:265–270. doi: 10.1016/0166-2236(89)90026-x. [DOI] [PubMed] [Google Scholar]
  38. Lipton SA, Nakanishi N. Shakespeare in Love – with NMDA receptors? Nature Med. 1999;5:270–271. doi: 10.1038/6481. [DOI] [PubMed] [Google Scholar]
  39. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613–621. doi: 10.1056/NEJM199403033300907. [DOI] [PubMed] [Google Scholar]
  40. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27:2846–2857. doi: 10.1523/JNEUROSCI.0116-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957;58:193–201. doi: 10.1001/archopht.1957.00940010205006. [DOI] [PubMed] [Google Scholar]
  42. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006;6:53–60. doi: 10.1016/j.coph.2005.12.002. [DOI] [PubMed] [Google Scholar]
  43. Neyton J, Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006;26:1331–1333. doi: 10.1523/JNEUROSCI.5242-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med. 2004;4:149–177. doi: 10.2174/1566524043479239. [DOI] [PubMed] [Google Scholar]
  45. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719–721. doi: 10.1126/science.164.3880.719. [DOI] [PubMed] [Google Scholar]
  46. Papadia S, Stevenson P, Hardingham NR, Bading H, Hardingham GE. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci. 2005;25:4279–4287. doi: 10.1523/JNEUROSCI.5019-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pohl D, Ishmaru MJ, Bittigau P, Stadhaus D, Hubner C, Olney JW, Turski L, Ikonomidou C. NMDA antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci U S A. 1999;96:2508–2513. doi: 10.1073/pnas.96.5.2508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pottorf WJ, 2nd, Johanns TM, Derrington SM, Strehler EE, Enyedi A, Thayer SA. Glutamate-induced protease-mediated loss of plasma membrane Ca2+ pump activity in rat hippocampal neurons. J Neurochem. 2006;98:1646–1656. doi: 10.1111/j.1471-4159.2006.04063.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Rameau GA, Tukey DS, Garcin-Hosfield ED, Titcombe RF, Misra C, Khatri L, Getzoff ED, Ziff EB. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci. 2007;27:3445–3455. doi: 10.1523/JNEUROSCI.4799-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature. 2000;403:316–321. doi: 10.1038/35002090. [DOI] [PubMed] [Google Scholar]
  51. Schwab BL, Guerini D, Didszun C, Bano D, Ferrando-May E, Fava E, Tam J, Xu D, Xanthoudakis S, Nicholson DW, Carafoli E, Nicotera P. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ. 2002;9:818–831. doi: 10.1038/sj.cdd.4401042. [DOI] [PubMed] [Google Scholar]
  52. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, Guzman E, Niessen S, Yates JR, 3rd, Takemori H, Okamoto M, Montminy M. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004;119:61–74. doi: 10.1016/j.cell.2004.09.015. [DOI] [PubMed] [Google Scholar]
  53. Sensi SL, Jeng JM. Rethinking the excitotoxic ionic milieu: the emerging role of Zn2+ in ischemic neuronal injury. Curr Mol Med. 2004;4:87–111. doi: 10.2174/1566524043479211. [DOI] [PubMed] [Google Scholar]
  54. Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 1998;20:727–740. doi: 10.1016/s0896-6273(00)81011-9. [DOI] [PubMed] [Google Scholar]
  55. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, Hardingham GE. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci. 2006;26:4509–4518. doi: 10.1523/JNEUROSCI.0455-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci. 1998;1:366–373. doi: 10.1038/1577. [DOI] [PubMed] [Google Scholar]
  57. Tashiro A, Sandler VM, Toni N, Zhao C, Gage FH. NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature. 2006;442:929–933. doi: 10.1038/nature05028. [DOI] [PubMed] [Google Scholar]
  58. Thomas CG, Miller AJ, Westbrook GL. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol. 2006;95:1727–1734. doi: 10.1152/jn.00771.2005. [DOI] [PubMed] [Google Scholar]
  59. Tompa P, Baki A, Schad E, Friedrich P. The calpain cascade. μ-Calpain activates m-calpain. J Biol Chem. 1996;271:33161–33164. doi: 10.1074/jbc.271.52.33161. [DOI] [PubMed] [Google Scholar]
  60. Torok K, Wilding M, Groigno L, Patel R, Whitaker M. Imaging the spatial dynamics of calmodulin activation during mitosis. Curr Biol. 1998;8:692–699. doi: 10.1016/s0960-9822(98)70275-1. [DOI] [PubMed] [Google Scholar]
  61. Tymianski M, Charlton MP, Carlen PL, Tator CH. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci. 1993;13:2085–2104. doi: 10.1523/JNEUROSCI.13-05-02085.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Wu GY, Deisseroth K, Tsien RW. Activity–dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A. 2001;98:2808–2813. doi: 10.1073/pnas.051634198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Yamaguchi A, Tamatani M, Matsuzaki H, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, Tohyama M. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem. 2001;276:5256–5264. doi: 10.1074/jbc.M008552200. [DOI] [PubMed] [Google Scholar]
  64. Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P, Bading H. Decoding NMDA receptor signaling: Identification of genomic programs specifying neuronal survival and death. Neuron. 2007;53:549–562. doi: 10.1016/j.neuron.2007.01.025. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Physiology are provided here courtesy of The Physiological Society

RESOURCES